AU2016302252B2 - Liquid polymer delivery system for extended administration of drugs - Google Patents

Liquid polymer delivery system for extended administration of drugs Download PDF

Info

Publication number
AU2016302252B2
AU2016302252B2 AU2016302252A AU2016302252A AU2016302252B2 AU 2016302252 B2 AU2016302252 B2 AU 2016302252B2 AU 2016302252 A AU2016302252 A AU 2016302252A AU 2016302252 A AU2016302252 A AU 2016302252A AU 2016302252 B2 AU2016302252 B2 AU 2016302252B2
Authority
AU
Australia
Prior art keywords
liquid polymer
liquid
composition
polymer
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016302252A
Other languages
English (en)
Other versions
AU2016302252A1 (en
Inventor
John Milton Downing
John Middleton
Vipin SAXENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tolmar International Ltd
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of AU2016302252A1 publication Critical patent/AU2016302252A1/en
Application granted granted Critical
Publication of AU2016302252B2 publication Critical patent/AU2016302252B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AU2016302252A 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs Active AU2016302252B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US62/200,198 2015-08-03
US201662275407P 2016-01-06 2016-01-06
US62/275,407 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (2)

Publication Number Publication Date
AU2016302252A1 AU2016302252A1 (en) 2018-02-22
AU2016302252B2 true AU2016302252B2 (en) 2022-01-20

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016302252A Active AU2016302252B2 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Country Status (19)

Country Link
US (3) US10786515B2 (https=)
EP (2) EP3804698B1 (https=)
JP (1) JP6949820B2 (https=)
KR (1) KR102696721B1 (https=)
CN (1) CN107920988B (https=)
AU (1) AU2016302252B2 (https=)
BR (1) BR112018002414B1 (https=)
CA (1) CA2994704A1 (https=)
DK (1) DK3331495T3 (https=)
EA (1) EA036951B1 (https=)
ES (2) ES2836805T3 (https=)
HR (1) HRP20201991T1 (https=)
HU (1) HUE052832T2 (https=)
IL (1) IL257221B (https=)
MX (1) MX378264B (https=)
PT (1) PT3331495T (https=)
TW (1) TWI718168B (https=)
WO (1) WO2017024027A1 (https=)
ZA (1) ZA201800591B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP6949820B2 (ja) 2015-08-03 2021-10-13 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
TW202027725A (zh) 2018-09-25 2020-08-01 愛爾蘭商托爾瑪國際有限公司 供藥物之延長投予之液體聚合物輸送系統
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
HUE069400T2 (hu) * 2019-09-30 2025-03-28 Tolmar International Ltd Folyékony polimer készítmények és rendszerek peptidek mint hatóanyagok nyújtott leadására
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
EP4221688A1 (en) * 2020-09-30 2023-08-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
WO2024117740A1 (ko) * 2022-11-28 2024-06-06 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
WO2024131788A1 (zh) * 2022-12-23 2024-06-27 长春金赛药业有限责任公司 一种GnRH拮抗剂可注射组合物及其制备方法和应用
EP4661840A2 (en) * 2023-02-10 2025-12-17 Tolmar International Limited Degarelix polymeric formulations
JP2026505354A (ja) * 2023-02-10 2026-02-13 トルマー インターナショナル リミテッド デガレリクスの有機溶媒製剤
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
WO2002030393A2 (en) * 2000-09-21 2002-04-18 Atrix Laboratories, Inc. Polymeric delivery formulations of leuprolide with improved efficacy
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
EP1334990A1 (en) 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
US20120225033A1 (en) 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
CA2618404A1 (en) 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US7740877B2 (en) 2006-04-07 2010-06-22 University Of Utah Research Foundation Aliphatically modified biodegradable block copolymers as thermogelling polymers
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2010085608A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
AP3138A (en) 2009-04-24 2015-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2012005594A2 (en) 2010-07-09 2012-01-12 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
KR20130100345A (ko) * 2010-11-04 2013-09-10 신닛테츠 수미킨 가가쿠 가부시키가이샤 하드코트층 부착 폴리카보네이트
US20140309202A1 (en) 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
DK2691079T3 (da) 2011-03-31 2020-09-28 Ingell Tech Holding B V Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning
HRP20192276T1 (hr) * 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
CA2852386C (en) * 2011-10-17 2019-05-21 Poly-Med, Inc. Absorbable in situ gel-forming system, method of making and use thereof
WO2015165976A1 (en) 2014-05-01 2015-11-05 Ingell Technologies Holding B.V. Liquid triblock copolymer
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP6949820B2 (ja) 2015-08-03 2021-10-13 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
US11752099B2 (en) 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
WO2002030393A2 (en) * 2000-09-21 2002-04-18 Atrix Laboratories, Inc. Polymeric delivery formulations of leuprolide with improved efficacy
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System

Also Published As

Publication number Publication date
WO2017024027A1 (en) 2017-02-09
US11779589B2 (en) 2023-10-10
PT3331495T (pt) 2020-12-07
US20240066039A1 (en) 2024-02-29
US20210060036A1 (en) 2021-03-04
US20180214459A1 (en) 2018-08-02
CN107920988B (zh) 2021-08-17
EA201890436A1 (ru) 2018-09-28
US12447158B2 (en) 2025-10-21
HRP20201991T1 (hr) 2021-02-05
TW201717960A (zh) 2017-06-01
HK1255638A1 (en) 2019-08-23
US10786515B2 (en) 2020-09-29
EP3804698B1 (en) 2024-01-31
JP6949820B2 (ja) 2021-10-13
BR112018002414A2 (pt) 2018-09-18
CA2994704A1 (en) 2017-02-09
ZA201800591B (en) 2021-07-28
MX378264B (es) 2025-03-10
EA036951B1 (ru) 2021-01-19
CN107920988A (zh) 2018-04-17
HUE052832T2 (hu) 2021-05-28
ES2975519T3 (es) 2024-07-08
DK3331495T3 (da) 2020-12-14
MX2018001499A (es) 2018-08-01
BR112018002414B1 (pt) 2023-11-21
IL257221B (en) 2022-01-01
EP3804698A1 (en) 2021-04-14
JP2018522906A (ja) 2018-08-16
KR20180030413A (ko) 2018-03-22
NZ739674A (en) 2024-10-25
EP3331495B1 (en) 2020-11-04
EP3331495A1 (en) 2018-06-13
AU2016302252A1 (en) 2018-02-22
ES2836805T3 (es) 2021-06-28
TWI718168B (zh) 2021-02-11
KR102696721B1 (ko) 2024-08-19
IL257221A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
US12447158B2 (en) Liquid polymer delivery system for extended administration of drugs
US8187640B2 (en) Low viscosity liquid polymeric delivery system
HK40051592B (en) Liquid polymer delivery system for extended administration of drugs
HK40051592A (en) Liquid polymer delivery system for extended administration of drugs
HK1255638B (en) Liquid polymer delivery system for extended administration of drugs
AU2020358364B2 (en) Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
HK40106993A (en) Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
HK40076745B (en) Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
HK40076745A (en) Liquid polymer compositions and systems for extended delivery of peptides as active pharmaceutical ingredients
HK1158115A (en) Low viscosity liquid polymeric delivery system

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)